EP 4214242 A1 20230726 - VECTORIZED ANTIBODIES FOR ANTI-VIRAL THERAPY
Title (en)
VECTORIZED ANTIBODIES FOR ANTI-VIRAL THERAPY
Title (de)
VEKTORISIERTE ANTIKÖRPER FÜR ANTIVIRALE THERAPIE
Title (fr)
ANTICORPS VECTORISÉS POUR THÉRAPIE ANTIVIRALE
Publication
Application
Priority
- US 202063078865 P 20200915
- US 202063106848 P 20201028
- US 2021050565 W 20210915
Abstract (en)
[origin: WO2022060916A1] Compositions and methods are described for the systemic delivery of anti-viral fully human post- translationally modified therapeutic monoclonal antibody against a viral pathogen to a human subject diagnosed with or at risk for a viral disease indicated for treatment or prophylaxis with the therapeutic mAb by administration of a gene therapy vector having the anti-viral pathogen antibody encoded by a transgene.
IPC 8 full level
C07K 16/40 (2006.01); A61P 7/10 (2006.01); A61P 31/14 (2006.01); C07K 16/10 (2006.01)
CPC (source: EP)
A61P 7/10 (2018.01); A61P 31/14 (2018.01); C07K 16/1003 (2023.08); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2319/02 (2013.01); C07K 2319/50 (2013.01); C12N 2750/14141 (2013.01); C12N 2799/022 (2013.01); C12N 2800/22 (2013.01); C12N 2830/008 (2013.01); C12N 2840/007 (2013.01)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
DOCDB simple family (application)
US 2021050565 W 20210915; EP 21789967 A 20210915